高危唾液腺肿瘤患者术后同期放化疗前瞻性Ⅱ期临床试验研究

doi:10.3760/cma.j.issn.1004-4221.2020.03.002

摘要
图/表
参考文献(32)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的评估术后辅助同期放化疗对具有高危预后因素的唾液腺肿瘤患者的疗效和安全性。方法入组2016-2018年间上海第九人民医院口腔颌面头颈肿瘤科收治的中度或高度恶性病理分级且伴有局部晚期Ⅲ/ⅣA期±切缘阳性/近切缘的唾液腺肿瘤术后患者52例。男35例,女17例,平均年龄55.5岁(21~73岁)。患者术后调强放疗和同期化疗。唾液腺腺癌患者同期化疗采用TP方案,淋巴上皮癌、鳞状细胞癌患者采用顺铂方案。结果 47例患者完成全部2周期同期化疗,5例患者完成1周期同期化疗。中位随访期为15.7个月(3.2~34.8个月),2年无瘤生存、总生存率分别为74%、98%。3例区域淋巴结复发,6例远处转移。3级放射性口腔黏膜炎30例,3级放射性皮肤损伤5例,3-4级中性粒细胞减少3例。DFS与术后辅助同期放化疗用药周期数呈正相关(P=0.006)。结论高危唾液腺肿瘤术后患者同期放化疗可获得较高的2年无瘤生存、总生存且可耐受的,长期结果仍需随机对照临床研究进一步证实。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王鑫
	窦圣金
	李烿烿
	吴思成
	陈刚
	张霖
	杨雯君
	朱国培

关键词 ：高危唾液腺肿瘤, 术后辅助, 同期放化疗, 前瞻性研究

Abstract：Objective To assess the efficacy and safety of post operative adjuvant concurrent chemoradiotherapy for patients with high-risk salivary gland tumors (SGT). Methods Fifty-two patients with moderate or high malignant pathological stage complicated with locally advanced stage Ⅲ/ⅣA±positive margin/close margin admitted to Shanghai Ninth People′s Hospital from 2016 to 2018 were enrolled in this study. Among them, 35 patients were male and 17 female with a median age of 55.5 years old (range:21-73 years old). All 52 patients were treated with intensity-modulated radiotherapy and concurrent chemotherapy. Patients with adeno carcinoma of the salivary gland receives concurrent chemotherapy with TP regimen. Patients with lympho epithelial cancer and squamous cell carcinoma were treated with cisplatin regimen.Results Forty-seven patients (90%) completed two cycles of concurrent chemotherapy,and five patients (10%) completed one cycle of concurrent chemotherapy. The median follow-up time was 15.7 months (3.2-34.8 months). The 2-year disease-free survival (DFS) and overall survival (OS) rates were 74% and 98%. Three patients experienced regional lymph recurrence and 6 cases had distant metastasis. Grade Ⅲ oral mucositis was observed in 30 patients. Grade Ⅲ dermatitis occurred in 5 cases. Only one patient experienced Grade IV neutropenia,and 2 patients developed Grade Ⅲ neutropenia. DFS was positively correlated with the cycle of postoperative adjuvant concurrent chemotherapy (P=0.006).Conclusions Patients with high-risk SGT can obtain higher 2-year DFS and OS rates and tolerable adverse events after postoperative concurrent chemoradiotherapy. Nevertheless, the long-term outcomes remain to be validated by randomized controlled clinical trials.

Key words： High-risk salivary gland tumor Postoperative adjuvant Concurrent chemoradiotherapy Prospective study

收稿日期: 2019-05-12

基金资助:上海市卫计委临床项目(201640158)

通讯作者: 朱国培,Email:antica@gmail.com

引用本文:

王鑫,窦圣金,李烿烿等. 高危唾液腺肿瘤患者术后同期放化疗前瞻性Ⅱ期临床试验研究[J]. 中华放射肿瘤学杂志, 2020, 29(3): 166-170.

Wang Xin,Dou Shengjin,Li Rongrong et al. Prospective phase Ⅱ study of postoperative concurrent chemoradiotherapy for patients with high-risk malignant salivary gland tumors[J]. Chinese Journal of Radiation Oncology, 2020, 29(3): 166-170.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2020.03.002 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2020/V29/I3/166

[1] Ettl T,Schwarz-Furlan S,Gosau M,et al. Salivary gland carcinomas[J]. Oral Maxillofac Surg 2012,16:267–283. DOI:10.1007/s10006-012-0350-9.
[2] EI-Naggar AK,Chan JK,Grandis JR,et al. WHO classification oftumors of head and neck tumours[M].4th ed. Lyon:IARC Press,2017:159-201.
[3] Cooper JS,Pajak TF,Forastiere AA,et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck[J]. N Engl J Med,2004,350(19):1937-1944. DOI:10.1056/NEJMoa032646.
[4] Bernier J,Domenge C,Ozsahin M,et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer[J]. N Engl J Med,2004,350:1945-1952. DOI:10.1056/NEJMoa032641.
[5] Terhaard CH,Lubsen H,Van der Tweel I,et al. Salivary gland carcinoma:independent prognostic factors for locoregional control,distantmetastases,and overall survival:Results of the dutch head and neck oncology cooperative group[J]. Head Neck,2004,26(8):681-693. DOI:10.1002/hed.10400.
[6] Guzzo M,Locati LD,Prott FJ,et al. Major and minor salivary gland tumors[J]. Crit Rev Oncol Hematol,2010,74:134-148. DOI:10.1016/j.critrevonc.2009.10.004.
[7] Harrison LB,Armstrong JG,Spiro RH,et al. Postoperative radiation therapy for major salivary gland malignancies[J]. J Surg Oncol,1990,45:52-55. DOI:10.1002/jso.2930450112.
[8] Cheung MC,Franzmann E,Sola JE,et al. A comprehensive analysis of parotid and salivary gland cancer:worse outcomes for male gender[J]. J Surg Res,2011,171(1):151-158. DOI:10.1016/j.jss.2009.11.721.
[9] Bell RB,Dierks EJ,Homer L,et al. Management and outcome of patients with malignant salivary gland tumors[J]. J Oral Maxillofac Surg,2005,63(5):917-928. DOI:10.1016/j.joms.2005.03.006.
[10] Pignon JP,leMaitre A,Maillard E,et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC):an update on 93 randomised trials and 17,346 patients[J]. Radiother Oncol,2009,92(1):4-14. DOI:10.1016/j.radonc.2009.04.014.
[11] Airoldi M,Cortesina G,Giordano C,et al. Update and perspectives on non-surgical treatment of salivary gland malignancies[J]. Acta Otorhinolaryngol Ital,2003,23(2):368-376.
[12] Gilbert J,Li Y,Pinto HA,et al. Phase Ⅱ trial of taxol in salivary gland malignancies (E1394):a trial of the Eastern Cooperative Oncology Group[J]. Head Neck,2006,28(1):197-204. DOI:10.1002/hed.20327.
[13] Van Herpen CML,Locati LD,Buter J,et al. PhaseⅡ study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)[J]. Eur J Cancer,2008,44:2542-2545. DOI:10.1016/j.ejca.2008.08.014.
[14] Airoldi M,Pedani F,Succo G,et al. PhaseⅡ randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies[J]. Cancer,2001,91(3):541-547. DOI:10.1002/1097-0142(20010201)91:3<541:AID-CNCR1032>3.0. CO;2-Y.
[15] Lagha A,Chraiet N,Ayadi M,et al. Systemic therapy in the management of metastatic or advanced salivary gland cancers[J]. Head Neck Oncol,2012,4(1):19. DOI:10.1186/1758-3284-4-19.
[16] Kaplan MJ,Johns ME,Cantell R,et al. Chemotherapy for salivary gland cancer[J]. Otolaryngol Head Neck Surg,1986,95(1):165-170. DOI:10.1177/019459988609500206.
[17] Suen JY,Johns M. Chemotherapy for salivery gland cancer[J]. Laryngoscope,1982,92(3):235-239. DOI:10.1288/00005537-198203000-00003.
[18] Laurie SA,Ho AL,Fury MG,et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands:a systematic review[J]. Lancet Oncol,2011,12(8):815-824. DOI:10.1016/S1470-2045(10)70245-X.
[19] Dreyfuss AI,Clark JR,Fallon BG,et al. Cyclophosphamide,doxorubicin,and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin[J]. Cancer,1987,60(12):2869-2872. DOI:10.1002/1097-0142(19871215)60:12<2869::AID-CNCR2820601203>3.0. CO;2-Y.
[20] Creagan ET,Woods JE,Rubin J,et al. Cisplatin based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck[J]. Cancer,1988,62(12):2313-2319. DOI:10.1002/1097-0142(19881201)62:11<2313:AID-CNCR2820621110>3.0. CO;2-4.
[21] Kasibhatla M,Kirkpatrick JP,Brizel DM. How much radiation is the chemotherapy worth in advanced head and neck cancer?[J]. Int J Radiat Oncol Biol Phys,2007,68(8):1491-1495. DOI:10.1016/j.ijrobp.2007.03.025
[22] Fowler JF. Correction to Kasibhatla et al. How much radiation is the chemotherapy worth in advanced head and neck cancer?[J]. Int J Radiat Oncol Biol Phys,2008,71(2):326-329. DOI:10.1016/j.ijrobp.2008.01.052.
[23] Pederson AW,Salama JK,Haraf DJ,et al. Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary glandmalignancies[J]. Head Neck Oncol,2011,3(1):31. DOI:10.1186/1758-3284-3-31.
[24] Rosenberg L,Weissler M,Hayes DN,et al. Concurrent chemoradiotherapy for locoregional advanced salivary gland malignancies[J]. Head Neck,2012,34(5):872-876. DOI:10.1002/hed.21831.
[25] Schoenfeld JD,Sher DJ,Norris CM Jr,et al. Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy[J]. Int J Radiat Oncol Biol Phys,2012,82(2):308-314. DOI:10.1016/j.ijrobp.2010.09.042.
[26] Tanvetyanon T,Qin D,Padhya T,et al. Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma[J]. Arch Otolaryngol Head Neck Surg,2009,135(7):687-692. DOI:10.1001/archoto.2009.70.
[27] Mifsud MJ,Tanvetyanon T,Mccaffrey JC,et al. Adjuvant radiotherapy versus concurrent chemoradiotherapy for the management of high-risk salivary gland carcinomas[J]. Head Neck,2016,38(11):1628-1633. DOI:10.1002/hed.24484.
[28] Gebhardt BJ,Ohr JP,Ferris RL,et al. Concurrent Chemoradiotherapy in the adjuvant treatment of high-risk primary salivary gland malignancies[J]. Am J Clin Oncol,2018,41(9):888-893. DOI:10.1097/COC.0000000000000386.
[29] Maruya S,Namba A,Matsubara A,et al. Salivary gland carcinoma treated with concomitant chemoradiation with intraarterial cisplatin and docetaxel[J]. Int J Clin Oncol,2006,11(5):403-406. DOI:10.1007/s10147-006-0587-0.
[30] Airoldi M,Fornari G,Pedani F,et al. Paclitaxel and carboplatin for recurrent salivary gland malignancies[J]. Anticancer Res,2000,20(5C):3781-3783. DOI:10.1097/00001813-200009000-00012.
[31] Li R,Dou S,Ruan M,et al. A feasibility and safety study of concurrent chemotherapy based on genetic testing in patients with high-risk salivary gland tumors[J]. Medicine,2018,97(17):e0564. DOI:10.1097/MD.0000000000010564.
[32] Szewczyk M,Golusinski P,Pazdrowski J,et al. Patterns of treatment failure in salivary gland cancers[J]. Rep Pract Oncol Radiother,2018,23(2):260-265. DOI:10.1016/j.rpor.2018.05.004.